{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"CRS Grade 1: temperature \\>=38°C without hypotension or hypoxia; Grade 2: temperature \\>=38°C with hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal cannula, facemask or blow-by; Grade 3: temperature \\>=38°C with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: temperature \\>=38°C with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (eg, continuous positive airway pressure \\[CPAP\\], bilevel positive airway pressure \\[BiPAP\\], intubation and mechanical ventilation); Grade 5: death.","reportingStatus":"NOT_POSTED","timeFrame":"From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)","title":"Number of Participants With Cytokine Release Syndrome (CRS) Graded According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria","type":"SECONDARY"}